Skip to main content
SpringerLink
Log in

Phase I study of combined alpha Interferon, alpha difluoromethylornithine (DFMO), and doxorubicin in advanced malignancy

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Interferon (IFN) and conventional cytotoxic chemotherapeutic agents have been successfully combined in various studies. Alpha difluoromethylornithine (DFMO) is a novel antitumor agent which is an inhibitor of polyamine metabolism. A phase I study of IFN 24 × 106 U/m2/day IM (days 3–7), DFMO 9 gm/m2 p.o. daily (days 1–7), and a variable dose of doxorubicin starting at 20 mg/m2 (day 6), of each 28 day cycle was performed. The aim of the study was to determine the maximally tolerable dose of doxorubicin in this combination. Three patients were treated with doxorubicin at 20 mg/m2 and six patients at 40 mg/m2. The dose limiting toxicities were neutropenia, fatigue and fever. All other toxicities were mild and there was no grade IV toxicity. A doxorubicin dose of 40 mg/m2 produced tolerable toxicity and is recommended for phase II studies. No major antitumor effects were seen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU: Alpha Interferon for induction of remission in hairy-cell leukemia. New Eng J of Med 310:15–18, 1984

    Google Scholar 

  2. Von Hoff DD:In vitro data supporting interferon plus cytotoxic agent combinations. Seminars in One 18:58–61, October 1991

    Google Scholar 

  3. Creagan ET, Frytak S, Long HJ, Kvols LK: Phase I study of Recombinant leukocyte A interferon (IFN-¶2A) with doxorubicin in advanced malignant disease. Cancer 64: 1034–1037, 1989

    Google Scholar 

  4. Green MD, Speyer JL, Hochster HS, Liebes LF, Dunleavy S, Widman T, Wernz JC, Blum RH, Spiegel RJ, Muggia FM: Phase I trial of escalating dose doxorubicin administered concurrently with ¶2-interferon. Cancer Research 48:2574–2578, 1988

    Google Scholar 

  5. Pegg AE, McCann PP: Polyamine metabolism & function. Am J Physiol 243:212–221, 1983

    Google Scholar 

  6. Mamont PS, Duchesne M, Grove J, Bey P: Anti-proliferative properties of DL-¶-difluoromethyl ornithine in cultured cells. A consequence of the irreversible inhibition of ornithine decarboxylase. Biochem Biophys Res Commun 81(l):58–66, 1978

    Google Scholar 

  7. Luk GD, Divin CI, Weissman RM, Baylin SB: Ornithine decarboxylase: essential in proliferation but not differentiation of human promyelocytic leukemia cells. Science 216:75–77, 1982

    Google Scholar 

  8. Luk GD, Goodwin G, Marton LJ, Baylin SB: Polyamines are necessary for the survival of human small-cell lung carcinoma in culture. Cell Biology 78:2355–2358, 1981

    Google Scholar 

  9. Kingsnorm AN, Russell WE, McCann PP, Diekema KA, Malt RA: Effects of ¶-difluoromethylornithine and 5-fluorouracil on the proliferation of a human colon adenocarcinoma cell line. Cancer Research 43:4035–4038, 1983

    Google Scholar 

  10. Sunkara PS, Fowler SK, Nishioka K, Rao PN: Inhibition of polyamine biosynthesis by ¶-difluoromethyl ornithine potentiates the cytotoxic effects of arabinosyl cytosine in hela cells. Biochem Biophys Res Commun 95:423–430, 1980

    Google Scholar 

  11. Hung DT, Deen DF, Seidenfeld J, Marton JL: Sensitization of 9L rat brain gliosarcoma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea by ¶-difluoromethylornithine, an ornithine decarboxylase inhibitor. Cancer Res 41: 2783–2785, 1981

    Google Scholar 

  12. Oredsson SM, Gray JW, Deen DF, Marton LJ: Decreased cytotoxicity of 1-β-D-arabinofuranosylcytosine in 9L rat brain tumor cells pretreated with ¶-difluoromethylornithinein vitro. Cancer Res 43:2541–2544, 1983

    Google Scholar 

  13. Edmonson JH, Kovach JS, Buckner JC, Kvols LK, Hahn RG: Phase I study of difluoromethylomithine in combination with recombinant ¶2a-interferon. Cancer Res 48: 6584–6586, 1988

    Google Scholar 

  14. Creagan ET, Long HJ, Ahmann DL, Schaid DJ: Phase II assessment of recombinant leukocyte A interferon with difluoromethylomithine in disseminated malignant melanoma. Am J Clin Oncol 13(3):218–220, 1990

    Google Scholar 

  15. Sunkara PS, Prakash NJ, Mayes GD, Sjoerdsma A: Tumor suppression with a combination of ¶-difluoromethyl ornithine and interferon. Science 219:851–853, 1983

    Google Scholar 

  16. Sarosy GA, Brown TD, Von Hoff DD, Spiegel RJ.

Download references

Author information

Authors and Affiliations

  1. Mayo Clinic, 55905, Rochester, MN, USA

    Vinod Ganju, John H. Edmonson & Jan C. Buckner

Authors
  1. Vinod Ganju
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John H. Edmonson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jan C. Buckner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ganju, V., Edmonson, J.H. & Buckner, J.C. Phase I study of combined alpha Interferon, alpha difluoromethylornithine (DFMO), and doxorubicin in advanced malignancy. Invest New Drugs 12, 25–27 (1994). https://doi.org/10.1007/BF00873231

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00873231

Key words

Search

Navigation